XLock Biosciences
XLock BioSciences: Innovating therapeutic chemokine proteins for effective drug development.
Founded
2022XLock BioSciences: Innovating therapeutic chemokine proteins for effective drug development.
Founded with a mission to revolutionize therapeutic drug development, XLock Biosciences focuses on creating novel engineered chemokine proteins. These proteins leverage well-understood biological mechanisms to address various medical challenges. As a pre-clinical stage biotechnology company, XLock Biosciences aims to overcome the complexities associated with chemokine-targeted drug development through advanced protein engineering. Their market focus is primarily on developing effective therapeutic solutions that can significantly improve patient outcomes.
XLock Biosciences has garnered attention from notable investors and industry experts due to its innovative approach. The company has achieved key milestones in securing funding and grants, which have propelled its research and development efforts. With a strong intellectual property portfolio and active participation in scientific conferences, XLock Biosciences is making a substantial impact in the field of biotechnology. The company's advancements in chemokine protein engineering hold promise for future therapeutic applications, potentially transforming the landscape of drug development.
Companies similar to XLock Biosciences include Terremoto Biosciences, Hyku, X4 Pharmaceuticals and Xios Therapeutics.
XLock Biosciences was founded in 2022.
XLock Biosciences' headquarters is located in Milwaukee, WI, US.
XLock Biosciences' most recent funding round was for $100k (USD) in January 2022.
As of Jan 10, 2022, XLock Biosciences has disclosed funding of $100k (USD). Undisclosed round amounts are excluded.
XLock Biosciences has 8 employees as of Feb 4, 2024.
Xios Therapeutics
